TABLE 2.

Pharmacokinetic parameters of piperacillin and tazobactam^a for eight anuric patients treated by CVVHD

Patient	Dose (g)	Interval (h)	kelb (liters/h)	t1/2β (h)	V (liters/kg)	CLtotal (ml/min)	CLCVVHD (ml/min)	FCVVHD (%)	SC
1	4, 0.5	12	0.172, 0.120	4.0, 5.8	0.27, 0.11	75, 22	25, 20	33, 92	0.94, 0.77
2	4, 0.5	24	0.159, 0.087	4.4, 7.9	0.25, 0.26	48, 27	20, 9	42, 33	0.80, 0.32
3	2, 0.25	8	0.173, 0.21	4.0, 5.6	0.22, 0.18	26, 26	27, NDc	100, ND	1.07, ND
4	2, 0.25	8	0.193, 0.193	3.6, 3.6	0.27, 0.24	44, 32	26, ND	59, ND	1.02, ND
5	4, 0.5	12	0.283, 0.124	2.5, 5.6	0.45, 0.29	220, 58	28, 23	13, 39	1.03, 0.82
6	4, 0.5	12	0.122, 0.128	5.7, 5.4	0.34, 0.41	42, 53	13, 19	31, 37	0.48, 0.69
7	4, 0.5	8	0.136, 0.215	6.2, 6.5	0.33, 0.26	46, 59	19, 19	41, 32	0.69, 0.69
8	4, 0.5	12	0.193, 0.173	3.6, 4.0	0.35, 0.15	72, 26	19, 13	26, 52	0.69, 0.48
Mean ± SD				0.179 ± 0.049, 0.156 ± 0.048	4.3 ± 1.2, 5.6 ± 1.3	0.31 ± 0.07, 0.24 ± 0.09		22 ± 5, 17 ± 5		0.84 ± 0.21, 0.64 ± 0.19
Median (range)							47 (26-220), 29.5 (22-59)		37 (13-100), 38 (32-92)

^aValues separated by a comma indicate those for piperacillin and tazobactam, respectively.

^bk_el, elimination rate constant.

^cND, not determined.